Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01197794 · ClinicalTrials.gov registry record · Phase 2
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,144
- Enrollment target
NCT01197794: Completed Phase 2 study, sponsored by AstraZeneca.
NCT01197794 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 1,144 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (760% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01197794, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,144 participants
- Enrollment target
Study Summary
The study will assess the efficacy, safety and tolerability of AZD1981 compared to non-active compound in asthmatic patients.
Primary Outcome
Change from baseline: treatment period average minus baseline. Treatment period average defined as the mean of all available data during randomized treatment that occurred on or prior to treatment failure. Treatment failure defined as worsening asthma symptoms resulting in increased dose of inhaled corticosteroid.
Interventions
- DRUG Placebo
- DRUG AZD1981
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,144 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
What the finished NCT01197794 record still lists
NCT01197794 is an interventional study that assigns participants to a tested intervention. Its 1,144 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (760% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01197794 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01197794 about?
NCT01197794 is a clinical study titled "Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients". The study will assess the efficacy, safety and tolerability of AZD1981 compared to non-active compound in asthmatic patients.
What is the current status of trial NCT01197794?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,144 participants. The study started on 2010-10. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01197794?
The interventions under investigation include: Placebo (DRUG), AZD1981 (DRUG).
Who is sponsoring clinical trial NCT01197794?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01197794's enrollment target sits among peer trials
1,144 20th of 2000 higher than 1,981 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06129864 · 1,145 participants · Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- NCT06676319 · 1,147 participants · Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
- NCT05894967 · 1,140 participants · NA
Moderators and Mediators of Perceptual Learning
- NCT06532487 · 1,140 participants · NA
Addressing Durable Health Disparities Through Critical Time Legal Interventions in Medically Underserved Latinx and Migrant Communities
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia